ed with both an increased risk of cumulative time admitted to hospital and joint risk of hospitalization and death.Among incident dialysis patients, a higher frailty severity as defined by the CFS is associated with both an increased risk of cumulative time admitted to hospital and joint risk of hospitalization and death. Patient involvement in dialysis decision-making is crucial, yet little is known about patient-reported outcomes over time on dialysis. To examine health-related outcomes over 24 and 36 months in an older cohort of dialysis patients. The "Dialysis outcomes in those aged ≥65 years study" is a prospective longitudinal cohort study of New Zealanders with kidney failure. Three New Zealand nephrology units. Kidney failure (dialysis and predialysis) patients aged 65 or above. We have previously described outcomes after 12 months of dialysis therapy relative to baseline. Patient-reported social and health factors using the SF-36, EQ-5D, and Kidney Symptom Score questionnaires. This article describes and compares characteristics of 120 older kidney failure patients according to whether they report "Same/better" or "Worse" health 24 and 36 months later, and identifies predictors of "worse health." Modified Poisson regression modeling estimated relative risks (RR) of worse health. Of 120 patients at 12 mis study, the majority of older dialyzing patients report "Same/better health" at 24 and 36 months. Māori and Pacific people report better outcomes on dialysis. Social and/or clinical interventions aimed at improving social satisfaction, sense of community, and help with usual activities may impact favorably on the experiences for older dialysis patients. Australian and New Zealand clinical trials registry ACTRN12611000024943.Australian and New Zealand clinical trials registry ACTRN12611000024943. Home hemodialysis (HHD) offers a flexible, patient-centered modality for patients with kidney failure. Growth in HHD is achieved by increasing the number of patients starting HHD and reducing attrition with strategies to prevent the modifiable reasons for loss. Our primary objective was to describe a Canadian HHD population in terms of technique failure and time to exit from HHD in order to understand reasons for exit. Our secondary objectives include the following (1) determining reasons for training failure, (2) reasons for early exit from HHD, and (3) timing of program exit. A retrospective cohort study of incident adult HHD patients between January 1, 2013-June 30, 2020. Alberta Kidney Care South, AKC-S HHD program. Patients who started training for HHD in AKC-S. A retrospective, cohort study of incident adult HHD patients with primary outcome time on home hemodialysis, secondary outcomes include reason for train failure, time to and reasons for technique failure. Cox-proportional hazard modelss. Reasons for exit differ according to duration on HHD. Early interventions aimed at reducing train failure and increasing psychosocial supports may help program growth.Training failure is a particularly important source of patient loss. Reasons for exit differ according to duration on HHD. Early interventions aimed at reducing train failure and increasing psychosocial supports may help program growth. Several trials had compared the efficacy and safety between non-vitamin K antagonist oral anticoagulants and warfarin for acute venous thromboembolism, but the results were incomplete. This updated review comprehensively assessed the efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism. Meta-analysis of randomised control trials. GsMTx4 molecular weight Six databases were searched from January 2000 to December 2018. Adult patients had got non-vitamin K antagonist oral anticoagulants or warfarin for venous thromboembolism. Randomised control trials that compared the efficacy and safety between non-vitamin K antagonist oral anticoagulants and warfarin. The efficacy and safety of non-vitamin K antagonist oral anticoagulants . Seven studies involving 29,879 cases were included, among which 14,943 cases were assigned to non-vitamin K antagonist oral anticoagulants group and 14,936 cases to warfarin group. Meta-analysis showed that compared with warfarin, recurrent venous thromboemboli as effective as warfarin, and has a better safety profile than warfarin.The Coronavirus disease 2019 (COVID-19) has spread worldwide since early 2020, and there are still no signs of resolution. The Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock (J-SSCG) 2020 Special Committee created the Japanese Rapid/Living recommendations on drug management for COVID-19 using the experience of creating the J-SSCGs. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to determine the certainty of the evidence and strength of the recommendations. The first edition of this guideline was released on September 9, 2020, and this document is the revised edition (ver. 3.1) (released on March 30, 2021). Clinical questions (CQs) were set for the following seven drugs favipiravir (CQ1), remdesivir (CQ-2), hydroxychloroquine (CQ-3), corticosteroids (CQ-4), tocilizumab (CQ-5), ciclesonide (CQ-6), and anticoagulants (CQ-7). Favipiravir is recommended for patients with mild COVID-19 not requiring supplemental oxygen (GRADE 2C); remdesivir for moderate COVID-19 patients requiring supplemental oxygen/hospitalization (GRADE 2B); hydroxychloroquine is not recommended for all COVID-19 patients (GRADE 1B); corticosteroids are recommended for moderate COVID-19 patients requiring supplemental oxygen/hospitalization (GRADE 1B) and severe COVID-19 patients requiring ventilator management/intensive care (GRADE 1A); however, their administration is not recommended for mild COVID-19 patients not requiring supplemental oxygen (GRADE 1B); tocilizumab is recommended for moderate COVID-19 patients requiring supplemental oxygen/hospitalization (GRADE 2B); and anticoagulant therapy for moderate COVID-19 patients requiring supplemental oxygen/hospitalization and severe COVID-19 patients requiring ventilator management/intensive care (GRADE 2C). We hope that these clinical practice guidelines will aid medical professionals involved in the care of COVID-19 patients.